237 related articles for article (PubMed ID: 21956710)
1. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
4. Insulin analogues and cancer risk: the emergence of second-generation studies.
Renehan AG
Diabetologia; 2012 Jan; 55(1):7-9. PubMed ID: 22033621
[TBL] [Abstract][Full Text] [Related]
5. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
6. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
7. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.
van Staa TP; Patel D; Gallagher AM; de Bruin ML
Diabetologia; 2012 Mar; 55(3):654-65. PubMed ID: 22127412
[TBL] [Abstract][Full Text] [Related]
9. Request for clarification from Ruiter et al regarding 'Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study'.
Carstensen B
Diabetologia; 2012 Mar; 55(3):857-8; author reply 859-60. PubMed ID: 22222505
[No Abstract] [Full Text] [Related]
10. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
11. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
12. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
Morden NE; Liu SK; Smith J; Mackenzie TA; Skinner J; Korc M
Diabetes Care; 2011 Sep; 34(9):1965-71. PubMed ID: 21775752
[TBL] [Abstract][Full Text] [Related]
13. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
Jonasson JM; Ljung R; Talbäck M; Haglund B; Gudbjörnsdòttir S; Steineck G
Diabetologia; 2009 Sep; 52(9):1745-54. PubMed ID: 19588120
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
17. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin.
Kostev K
Diabetologia; 2012 May; 55(5):1554-5. PubMed ID: 22349110
[No Abstract] [Full Text] [Related]
18. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
19. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
20. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]